Literature DB >> 15034304

A portrait of AKT kinases: human cancer and animal models depict a family with strong individualities.

Alfonso Bellacosa1, Joseph R Testa, Robert Moore, Lionel Larue.   

Abstract

More than a decade after their discovery, the three AKT kinase family members have emerged as central players in the signaling cascades that regulate cell growth, proliferation, survival and various aspects of intermediary metabolism. The mechanisms of activation of AKT kinases have been defined in relatively precise terms and new substrates are currently being validated in vivo. However, it is presently unclear whether AKT1, AKT2 and AKT3 are functionally redundant or whether each one performs specific functional role(s). In this review, we will summarize the signaling properties and highlight the specificities of AKT kinases that have emerged from the study of human cancer and animal models. While AKT kinases are an attractive target for pharmacological intervention, knowledge of the precise individual roles of AKT family members will improve the design of highly specific AKT-based therapeutics having reduced toxicity and improved efficacy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15034304     DOI: 10.4161/cbt.3.3.703

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  42 in total

1.  Oxidation of Akt2 kinase promotes cell migration and regulates G1-S transition in the cell cycle.

Authors:  Revati Wani; N Sharmila Bharathi; Jeffrey Field; Allen W Tsang; Cristina M Furdui
Journal:  Cell Cycle       Date:  2011-10-01       Impact factor: 4.534

2.  Detection of functional single-nucleotide polymorphisms that affect apoptosis.

Authors:  Sandra L Harris; German Gil; Harlan Robins; Wenwei Hu; Kim Hirshfield; Elisabeth Bond; Gareth Bond; Arnold J Levine
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-31       Impact factor: 11.205

3.  PHLPP1 mediates melanoma metastasis suppression through repressing AKT2 activation.

Authors:  Yanlin Yu; Meng Dai; Andrew Lu; Ellen Yu; Glenn Merlino
Journal:  Oncogene       Date:  2018-02-02       Impact factor: 9.867

4.  Akt1 in the cardiovascular system: friend or foe?

Authors:  Brian T O'Neill; E Dale Abel
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

5.  Downregulation of Epidermal Growth Factor Receptor Expression Contributes to alpha-TEA's Proapoptotic Effects in Human Ovarian Cancer Cell Lines.

Authors:  Ming-Chieh Shun; Weiping Yu; Sook-Kyung Park; Bob G Sanders; Kimberly Kline
Journal:  J Oncol       Date:  2010-03-04       Impact factor: 4.375

6.  Connexin43 and zonula occludens-1 are targets of Akt in cardiomyocytes that correlate with cardiac contractile dysfunction in Akt deficient hearts.

Authors:  Sangmi Ock; Wang Soo Lee; Hyun Min Kim; Kyu-Sang Park; Young-Kook Kim; Hyun Kook; Woo Jin Park; Tae Jin Lee; E D Abel; Jaetaek Kim
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-01-31       Impact factor: 5.187

Review 7.  NADPH oxidase-dependent signaling in endothelial cells: role in physiology and pathophysiology.

Authors:  Randall S Frey; Masuko Ushio-Fukai; Asrar B Malik
Journal:  Antioxid Redox Signal       Date:  2009-04       Impact factor: 8.401

Review 8.  The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.

Authors:  Subbarao V Madhunapantula; Gavin P Robertson
Journal:  Pigment Cell Melanoma Res       Date:  2009-05-28       Impact factor: 4.693

9.  Requirement of the Akt/beta-catenin pathway for uterine carcinosarcoma genesis, modulating E-cadherin expression through the transactivation of slug.

Authors:  Makoto Saegusa; Miki Hashimura; Takeshi Kuwata; Isao Okayasu
Journal:  Am J Pathol       Date:  2009-04-23       Impact factor: 4.307

10.  Benzene polyphosphates as tools for cell signalling: inhibition of inositol 1,4,5-trisphosphate 5-phosphatase and interaction with the PH domain of protein kinase Balpha.

Authors:  Stephen J Mills; Fabrice Vandeput; Melanie N Trusselle; Stephen T Safrany; Christophe Erneux; Barry V L Potter
Journal:  Chembiochem       Date:  2008-07-21       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.